Share Name Share Symbol Market Type Share ISIN Share Description
Amphion Innovations Plc LSE:AMP London Ordinary Share GB00B0DJNP99 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.15 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.11 -13.64 -7.29
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.15 GBX

Amphion Innovations (AMP) Latest News

More Amphion Innovations News
Amphion Innovations Takeover Rumours

Amphion Innovations (AMP) Discussions and Chat

Amphion Innovations (AMP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Amphion Innovations trades in real-time

Amphion Innovations (AMP) Top Chat Posts

Amphion Innovations Daily Update: Amphion Innovations Plc is listed in the General Financial sector of the London Stock Exchange with ticker AMP. The last closing price for Amphion Innovations was 0.15p.
Amphion Innovations Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 0p while the 1 year low share price is currently 0p.
There are currently 209,175,888 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Amphion Innovations Plc is £313,763.83.
sorksandnorks: Good to see some views on AMP being aired. From the AMP website, it appears that AMP has holdings in the following companies. They are listed showing the % held by AMP and my estimate of their values - I have been very strict with these and some of those marked "nil value" may very well be worth something but I am considering the worst case scenario. Access - 15.07% - nil value Firestar - 11.86% - nil value Polarean - 24.0% - today's market cap = £11.7m, hence AMP's share = £2.8m MotifBio - 9.5% - today's market cap = £102.3m, hence AMP's share = £9.7m Private Markets - 25.33% - nil value Wellgen - 24.34% - nil value Datatern - 100% - nil value From this, AMP's market cap today should be £2.8m + £9.7m = £12.5m. But, on ADVFN this morning, AMP's market cap = £1.7m and AMP's mid share price = 0.8p. So, ignoring any debt, AMP's mid share price should be (12.5/1.7) x 0.8 = 5.88p. The problem, of course, is the debt and I do not know how much that is. If anyone does can they please post it on this board so that I can work out what I think the mid share price should be. Many thanks.
gclark: Been trying to work out the reasons. What is coming up soon is a MotifBio fund raise. Amphion doesn't have the money to take part in the fund raise so maybe these directors want to raise funds separately to replace Amphion in the fund raise. When the MotifBio fund raise takes place, our share of MotifBio will reduce, perhaps from 14% to 11/12% but that is life. I am still a buyer of Amphion as it has assets in good companies in my view, and it has a good gearing on share price increases in the two quoted companies. IMV
gclark: I agree PJJ. I've worked the gearing out at 1:4, so a doubling of MTFB share price will see a x4 increase in AMP. But it depends at what price you buy AMP, and that was from a lower price. And I am also invested in MTFB. I am convinced by their Ph3 results and that they will get FDA approval. A new antibiotic with an under-used mode of action is unlikely to be rejected in my view, and I think there would be bad publicity for the FDA and their objective of encouraging the development of antibiotics if it was refused, given the evidence of non-inferiority to vancomycin. Unless there is something wrong with the trials or the data ... but I don't think so. AIMO
hoggar: Amphion issued the usual caveats ... "there can be no assurance as to whether or when the IPO of Polarean may be completed, or as to the actual size or final terms of the IPO". The above header is quoted from a leading online investment analyst magazine today. Sounds familiar, yep you are right. If investors in this dire company had reservations and doubts whether Amphion will indeed float Polarean before 2018 then this RNS confirms what investors have been stating on this thread for many months. The company is flat broke, and worst still, their only hope of attracting reasonable funding is currently performing like a chocolate fireguard. They were of course counting on Motif share price to be double/plus its current standing by now. This seems very unlikely until all nuts and bolts and FDA approvals are in place which may not be until Q3 next year. So will they review their last statement and not sell Motif stock? My guess is they will be forced to sell at or around the current price and take their holding below 10%
hoggar: Confidence is the optimal word with this company. It’s no wonder Amphion cannot attract funding while its share price in firmly classified as junk status. Amphion directors primary task is to secure funding for partner companies. It would appear Amphion had no input with the fund raising Motif has just secured. I think that just about says it all with this outfit.
escapetohome: No confidence whatsoever in this company, not one shred, and the share price reflects my opinion.
hoggar: I posted here recently the implications and the improbability of Amphion gaining any favourable Federal judgement from the 402 and 502 Microstrategy case. In other words Amphion have run out of money and these patents are now worthless from December 2017. In brief, Amphion have spent millions and borrowed millions employing useless inept so-called patent lawyers in the states fighting SAP, Microsoft etc for many years. There is no doubt the patents were valid but now they are not! So today’s announcement that Amphion will continue to explore further means of funding and borrowing to pursue more litigation is totally ridiculous. This announcement also indicates that Amphion will use any profits from the share price in Motif and Polareon to fund further borrowing. Investors need to consider if this bunch of mindless directors at Amphion are of sound mind.
debbie_does_dallas_twice: Look at the facts and not dagenham dave's bitter spiteful deramps.. The shares now have a circa value of 5p with mtfb at 50p Financial Results (note how a 4p recovery on mtfb changed the nav by 1.4p.) this was when the price was 31p). -- Net Asset Value ("NAV") per share was -1p (US -$0.02 cents)* at Period-end from -2.4p (US -$0.03 cents) as at year end. This increase was due almost entirely to the movement in value of the Motif Bio plc share price Highlights Amphion
bullet ant: That was before mtfb price up nearly 40% today Financial Results -- Net Asset Value ("NAV") per share was -1p (US -$0.02 cents)* at Period-end from -2.4p (US -$0.03 cents) as at year end. This increase was due almost entirely to the movement in value of the Motif Bio plc share price Highlights Amphion -- Sold the Company's remaining holding of Kromek Group plc -- Richard Morgan and Robert Bertoldi, Directors of the Company, entered into a Deed of Postponement where they agreed to postpone the repayment of the amounts owed to them, which total US $4.3 million, until all other debts of the Company are repaid Motif Bio -- In January, Motif Bio completed treatment of patients in its Phase III trial (REVIVE-1) for its product candidate iclaprim -- In April, Motif Bio released data readout from REVIVE-1, showing iclaprim to be well tolerated and met the non-inferiority margin mandated by the FDA Polarean
shackleton1: Kromek tipped in The Sunday Mail. This will be good for the AMP share price tomorrow.
Amphion Innovations share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Amphion In..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200921 07:25:10